Authors: Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Up to -20.9% mean weight loss at 72 weeks at highest dose
Obesity is a chronic disease contributing to substantial morbidity. In this phase 3 double-blind, randomized, controlled trial, 2,539 adults with a BMI >= 30 were assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks.
Multinational phase 3 trial establishing substantial and sustained body-weight reductions of up to 20.9% with dual GIP/GLP-1 receptor co-agonist tirzepatide.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
